A DNA sequence imposed over binary code, in reference to MedTech

[On-demand Webinar] Will Covid-19 Accelerate the Next Wave of Adoption of Next-Generation Sequencing (NGS) in Healthcare?

Sequencing-based diagnostic testing has been on the uptrend, with the adoption of next-generation sequencing (NGS) testing in oncology, genetics and prenatal screening – areas where the vast majority is done – continuing to grow strongly.

Now, sequencing looks set to become even more integral in the healthcare system with the Covid-19 pandemic highlighting the power of sequencing-based diagnostic testing in global efforts to combat the spread of the infectious disease; and its importance in supporting recovery efforts. In the evolving market for diagnostics, how and where can sequencing companies and other IVD players find growth opportunities.

EIU Healthcare hosted the “Will Covid-19 Accelerate the Next Wave of Adoption of Next-Generation Sequencing (NGS) in Healthcare” webinar to discuss the global market outlook for NGS, covering:

  • How has Covid-19 impacted EIU Healthcare’s forecast data on the global NGS market (with focus in Asia-Pacific and Europe markets) – for sequencing instruments and in test areas such as oncology, NIPT and infectious diseases? When can growth recovery be expected?
  • What is the longer-term outlook on sequencing-based testing opportunities in these areas?
  • How is increasing competition posed by rising domestic players in countries such as China and new commercial models shaping the market?
  • How will the market for NGS testing evolve as technology development is expected to reduce the operational cost of NGS testing for smaller volume labs?
  • How will the growing adoption of NGS impact the use of other competing diagnostic technologies in areas such as molecular diagnostics and tissue diagnostics?
  • The webinar session is now available on-demand.

IVD Gateway

The go-to-source for Covid-19 impact on In-Vitro Diagnostics test demand in 2020 and market recovery trends in 2021 for all 115 IVD test segments across countries in Asia, Europe and Latin America.